Impax Asset Management Group plc acquired a new position in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX – Free Report) in the third quarter, Holdings Channel reports. The fund acquired 10,234 shares of the company’s stock, valued at approximately $5,344,000.
Several other hedge funds and other institutional investors also recently modified their holdings of IDXX. Bank of New York Mellon Corp acquired a new position in shares of IDEXX Laboratories in the second quarter valued at approximately $628,223,000. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC raised its stake in shares of IDEXX Laboratories by 4.6% during the second quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 911,489 shares of the company’s stock worth $479,844,000 after purchasing an additional 39,700 shares during the last quarter. Arrowstreet Capital Limited Partnership raised its stake in shares of IDEXX Laboratories by 52.4% during the first quarter. Arrowstreet Capital Limited Partnership now owns 838,839 shares of the company’s stock worth $471,335,000 after purchasing an additional 288,471 shares during the last quarter. Dimensional Fund Advisors LP raised its stake in shares of IDEXX Laboratories by 4.3% during the first quarter. Dimensional Fund Advisors LP now owns 573,332 shares of the company’s stock worth $322,145,000 after purchasing an additional 23,582 shares during the last quarter. Finally, Alyeska Investment Group L.P. lifted its holdings in shares of IDEXX Laboratories by 97.3% during the second quarter. Alyeska Investment Group L.P. now owns 401,082 shares of the company’s stock worth $211,146,000 after purchasing an additional 197,808 shares during the period. 87.84% of the stock is currently owned by hedge funds and other institutional investors.
Wall Street Analysts Forecast Growth
A number of equities analysts recently weighed in on IDXX shares. Weiss Ratings upgraded shares of IDEXX Laboratories from a “hold (c)” rating to a “hold (c+)” rating in a research report on Thursday, October 8th. Citigroup boosted their price objective on shares of IDEXX Laboratories from $650.00 to $670.00 and gave the company a “neutral” rating in a research note on Wednesday, August 5th. The Goldman Sachs Group began coverage on shares of IDEXX Laboratories in a research report on Friday, October 16th. They set a “buy” rating and a $740.00 price objective for the company. BTIG Research dropped coverage on shares of IDEXX Laboratories in a research note on Friday, October 30th. They issued a “buy” rating for the company. Finally, KeyCorp started coverage on shares of IDEXX Laboratories in a research note on Monday, October 12th. They issued a “sector weight” rating for the company. Seven research analysts have rated the stock with a Buy rating and six have assigned a Hold rating to the company’s stock. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average price target of $717.27.
View Our Latest Research Report on IDEXX Laboratories
IDEXX Laboratories Price Performance
IDEXX Laboratories stock opened at $698.47 on Thursday. The company has a market cap of $55.03 billion, a P/E ratio of 47.10 and a beta of 1.55. IDEXX Laboratories, Inc. has a one year low of $500.61 and a one year high of $769.98. The business has a fifty day moving average of $572.78 and a two-hundred day moving average of $573.79. The company has a debt-to-equity ratio of 0.16, a quick ratio of 0.88 and a current ratio of 1.19.
IDEXX Laboratories (NASDAQ:IDXX – Get Free Report) last posted its quarterly earnings results on Monday, November 2nd. The company reported $3.96 earnings per share for the quarter, topping analysts’ consensus estimates of $3.71 by $0.25. The business had revenue of $1.21 billion for the quarter, compared to analysts’ expectations of $1.19 billion. IDEXX Laboratories had a net margin of 25.36% and a return on equity of 71.04%. The business’s revenue for the quarter was up 9.9% on a year-over-year basis. During the same period in the prior year, the company posted $3.22 EPS. As a group, analysts predict that IDEXX Laboratories, Inc. will post 15.05 earnings per share for the current fiscal year.
Insider Transactions at IDEXX Laboratories
In other IDEXX Laboratories news, Director Daniel M. Junius sold 1,200 shares of the company’s stock in a transaction dated Wednesday, November 4th. The shares were sold at an average price of $704.07, for a total transaction of $844,884.00. Following the transaction, the director directly owned 2,361 shares in the company, valued at approximately $1,662,309.27. This represents a 33.70% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, EVP Michael Lane sold 3,979 shares of the company’s stock in a transaction dated Wednesday, November 4th. The stock was sold at an average price of $688.64, for a total transaction of $2,740,098.56. Following the transaction, the executive vice president owned 4,076 shares in the company, valued at $2,806,896.64. The trade was a 49.40% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last three months, insiders have sold 41,428 shares of company stock valued at $28,567,934. 0.79% of the stock is owned by company insiders.
IDEXX Laboratories Company Profile
IDEXX Laboratories develops and sells diagnostic, technology and software products for veterinary, livestock and water-testing markets. Its veterinary offerings include in-clinic diagnostic instruments and tests, reference laboratory services, digital imaging and practice-management software that help veterinary professionals assess animal health and manage their practices. The company also provides diagnostic tests and related services for livestock and poultry, as well as products used to monitor water quality.
See Also
- Five stocks we like better than IDEXX Laboratories
- Drilling for Yield in the Gulf: Chevron Drops Anchor in Deepwater
- TJX Stock Flashes a Strong Bullish Signal as Its $3 Billion Buyback Plan Takes Shape
- Viking’s Low-Water Miss Looks Like a Buy-the-Dip Opportunity
- Why Amazon Wants the Chips and Blackstone Wants the Buildings
Want to see what other hedge funds are holding IDXX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for IDEXX Laboratories, Inc. (NASDAQ:IDXX – Free Report).
Receive News & Ratings for IDEXX Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IDEXX Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.
